Sectors News Results

  • Celgene, Bristol Clear Way For Merger -- WSJ

    This article is being republished as part of our daily reproduction of WSJ.com articles that also appeared in the U.S. print edition of The Wall Street Journal. Bristol-Myers Squibb Co. (BMY) took a major step toward completing its $74 billion acquisition of Celgene Corp. (CELG), as the two pharmaceutical companies found a buyer for a skin treatment whose sale they hope will address antitrust concerns. Amgen Inc. (AMGN) agreed on Monday to buy Celgene's (CELG) psoriasis medicine Otezla for $13.4...

Search News

Filter Results

Publication Date
Topic
Provider

News, commentary and research reports are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.